Skip to main content

Table 2 High cost noted in 25 CDR reports with a negative reimbursement recommendation

From: Health technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and cost

 

Prevalence of treated disorder (per 100,000)

p-value

<50 to >10

≤10 to >1

≤1

n = 5

n = 10

n = 10

No. with high cost or need for price reduction stated in the recommendation

0 (0.0%)

6 (60.0%)

5 (50.0%)

0.132

No. with high cost noted elsewhere in the report

0 (0.0%)

1 (10.0%)

3 (30.0%)

0.109

No. with high cost or need for price reduction noted anywhere in the report

0 (0.0%)

7 (70.0%)

8 (80.0%)

0.006

  1. CDR Common Drug Review